Biolojic’s BD9 is a multibody that was computationally designed as a multi specific antibody targeting IL-13 / TSLP to treat inflammatory diseases.
Agreement builds on Teva's Pivot to Growth strategy to step up innovation on Teva's innovative pipeline.
Teva to obtain exclusive worldwide rights to develop and commercialize BD9 multibody for potential treatment for Atopic Dermatitis and Asthma
https://finance.yahoo.com/news/teva-biolojic-design-announce-exclusive-133000897.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.